{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:01:54Z","timestamp":1790661714034,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12955-016-0449-z","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T23:40:29Z","timestamp":1458862829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-0882","authenticated-orcid":false,"given":"Emily Nash","family":"Smyth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Melemed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astra M.","family":"Liepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"449_CR1","unstructured":"American Cancer Society. Global Cancer Facts & Figures 2nd Edition. American Cancer Society, Atlanta. 2011. http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-027766.pdf . Accessed 4 Aug, 2014."},{"key":"449_CR2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2217\/fon.12.61","volume":"8","author":"JR Benson","year":"2012","unstructured":"Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8:697\u2013702.","journal-title":"Future Oncol"},{"key":"449_CR3","unstructured":"Swain S, Kim S, Cortes J, J. R, Semiglazov V, Campone M, et al. 350O_PR - Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1\u00a0L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology; 28.09.2014; Madrid, Spain 2014."},{"key":"449_CR4","first-page":"877","volume-title":"Diseases of the Breast","author":"SH Tan","year":"2010","unstructured":"Tan SH, Wolff AC. Treatment of Metastatic Breast Cancer: Chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast, vol. 74. 4th ed. Philadelphia, PA: Lippincott-Raven Publishers; 2010. p. 877\u2013919.","edition":"4"},{"key":"449_CR5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-27-32","volume":"27","author":"A Montazeri","year":"2008","unstructured":"Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.","journal-title":"J Exp Clin Cancer Res"},{"key":"449_CR6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.pop.2009.08.001","volume":"36","author":"PA Ganz","year":"2009","unstructured":"Ganz PA. Survivorship: adult cancer survivors. Prim Care. 2009;36:721\u201341.","journal-title":"Prim Care"},{"key":"449_CR7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","volume":"26","author":"CC Gotay","year":"2008","unstructured":"Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355\u201363.","journal-title":"J Clin Oncol"},{"key":"449_CR8","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11136-006-0003-2","volume":"15","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2006;15:1297\u2013306.","journal-title":"Qual Life Res"},{"key":"449_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11136-008-9413-7","volume":"18","author":"KN Lohr","year":"2009","unstructured":"Lohr KN, Zebrack BJ. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual Life Res. 2009;18:99\u2013107.","journal-title":"Qual Life Res"},{"issue":"8","key":"449_CR10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0959-8049(98)00018-5","volume":"34","author":"SB Detmar","year":"1998","unstructured":"Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: a feasibility study. Eur J Cancer. 1998;34(8):1181\u20136.","journal-title":"Eur J Cancer"},{"key":"449_CR11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6600001","volume":"86","author":"G Velikova","year":"2002","unstructured":"Velikova G, Brown JM, Smith AB, Selby PJ. Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology. Br J Cancer. 2002;86:51\u20139.","journal-title":"Br J Cancer"},{"key":"449_CR12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","volume":"22","author":"G Velikova","year":"2004","unstructured":"Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22:714\u201324.","journal-title":"J Clin Oncol"},{"key":"449_CR13","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1001\/jama.288.23.3027","volume":"288","author":"SB Detmar","year":"2002","unstructured":"Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027\u201334.","journal-title":"JAMA"},{"key":"449_CR14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","volume":"32","author":"G Kotronoulas","year":"2014","unstructured":"Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32:1480\u2013501.","journal-title":"J Clin Oncol"},{"key":"449_CR15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016;34:557\u201365.","journal-title":"J Clin Oncol"},{"issue":"9","key":"449_CR16","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/annonc\/mdv181","volume":"26","author":"D Howell","year":"2015","unstructured":"Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26(9):1846\u201358.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"449_CR17","doi-asserted-by":"crossref","first-page":"v15","DOI":"10.1093\/annonc\/mdq160","volume":"21","author":"F Cardoso","year":"2010","unstructured":"Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v15\u20139.","journal-title":"Ann Oncol"},{"key":"449_CR18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jnci\/81.7.485","volume":"81","author":"CM Moinpour","year":"1989","unstructured":"Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens Jr FL, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst. 1989;81:485\u201395.","journal-title":"J Natl Cancer Inst"},{"key":"449_CR19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1748-717X-4-10","volume":"4","author":"C Nieder","year":"2009","unstructured":"Nieder C, Mehta MP. Prognostic indices for brain metastases--usefulness and challenges. Radiat Oncol. 2009;4:10.","journal-title":"Radiat Oncol"},{"key":"449_CR20","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1200\/JCO.2007.11.7275","volume":"25","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Wenzel L, Shaw E, Cella D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol. 2007;25:5058\u201362.","journal-title":"J Clin Oncol"},{"key":"449_CR21","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.4065\/82.10.1244","volume":"82","author":"EA Hahn","year":"2007","unstructured":"Hahn EA, Cella D, Chassany O, Fairclough DL, Wong GY, Hays RD, et al. Precision of health-related quality-of-life data compared with other clinical measures. Mayo Clin Proc. 2007;82:1244\u201354.","journal-title":"Mayo Clin Proc"},{"key":"449_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/02841860903440288","volume":"49","author":"MA Sprangers","year":"2010","unstructured":"Sprangers MA. Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol. 2010;49:155\u201363.","journal-title":"Acta Oncol"},{"key":"449_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.28382","volume":"120","author":"C Quinten","year":"2014","unstructured":"Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120:302\u201311.","journal-title":"Cancer"},{"key":"449_CR24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.lungcan.2012.09.002","volume":"78","author":"M Reck","year":"2012","unstructured":"Reck M, Thatcher N, Smit EF, Lorigan P, Szutowicz-Zielinska E, Liepa AM, et al. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer. 2012;78:276\u201381.","journal-title":"Lung Cancer"},{"key":"449_CR25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","volume":"10","author":"C Quinten","year":"2009","unstructured":"Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865\u201371.","journal-title":"Lancet Oncol"},{"key":"449_CR26","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1200\/JCO.1992.10.12.1833","volume":"10","author":"A Coates","year":"1992","unstructured":"Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol. 1992;10:1833\u20138.","journal-title":"J Clin Oncol"},{"key":"449_CR27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ejca.2004.01.014","volume":"40","author":"F Efficace","year":"2004","unstructured":"Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004;40:1021\u201330.","journal-title":"Eur J Cancer"},{"key":"449_CR28","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0959-8049(00)00144-1","volume":"36","author":"JA Kramer","year":"2000","unstructured":"Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer. 2000;36:1498\u2013506.","journal-title":"Eur J Cancer"},{"key":"449_CR29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12032-011-9844-9","volume":"29","author":"H Svensson","year":"2012","unstructured":"Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol. 2012;29:432\u20138.","journal-title":"Med Oncol"},{"key":"449_CR30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00520-006-0165-z","volume":"15","author":"D Gupta","year":"2007","unstructured":"Gupta D, Granick J, Grutsch JF, Lis CG. The prognostic association of health-related quality of life scores with survival in breast cancer. Support Care Cancer. 2007;15:387\u201393.","journal-title":"Support Care Cancer"},{"key":"449_CR31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1524-4741.2011.01151.x","volume":"17","author":"ED Staren","year":"2011","unstructured":"Staren ED, Gupta D, Braun DP. The prognostic role of quality of life assessment in breast cancer. Breast J. 2011;17:571\u20138.","journal-title":"Breast J"},{"key":"449_CR32","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2004.07.089","volume":"22","author":"L Collette","year":"2004","unstructured":"Collette L, van Andel G, Bottomley A, Oosterhof GO, Albrecht W, de Reijke TM, et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 2004;22:3877\u201385.","journal-title":"J Clin Oncol"},{"key":"449_CR33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<173::AID-CNCR23>3.0.CO;2-T","volume":"83","author":"VT Chang","year":"1998","unstructured":"Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, Portenoy RK. Quality of life and survival: the role of multidimensional symptom assessment. Cancer. 1998;83:173\u20139.","journal-title":"Cancer"},{"key":"449_CR34","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","volume":"22","author":"I Chau","year":"2004","unstructured":"Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395\u2013403.","journal-title":"J Clin Oncol"},{"key":"449_CR35","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/annonc\/mdl183","volume":"17","author":"F Efficace","year":"2006","unstructured":"Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, et al. Is a patient\u2019s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17:1698\u2013704.","journal-title":"Ann Oncol"},{"key":"449_CR36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/sj.bjc.6604248","volume":"98","author":"M McKernan","year":"2008","unstructured":"McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer. 2008;98:888\u201393.","journal-title":"Br J Cancer"},{"key":"449_CR37","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1200\/JCO.2009.23.7420","volume":"27","author":"B Movsas","year":"2009","unstructured":"Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27:5816\u201322.","journal-title":"J Clin Oncol"},{"key":"449_CR38","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2010.33.4631","volume":"30","author":"JA Sloan","year":"2012","unstructured":"Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, et al. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol. 2012;30:1498\u2013504.","journal-title":"J Clin Oncol"},{"issue":"Suppl1","key":"449_CR39","first-page":"9515","volume":"26","author":"AD Tan","year":"2007","unstructured":"Tan AD, Novotny PJ, Kaur JS, Buckner JC, Schaefer PL, Stella PJ, et al. A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol. 2007;26(Suppl1):9515.","journal-title":"J Clin Oncol"},{"key":"449_CR40","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","volume":"26","author":"KS Albain","year":"2008","unstructured":"Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950\u20137.","journal-title":"J Clin Oncol"},{"key":"449_CR41","unstructured":"Cleeland C. The Brief Pain Inventory: A Users Guide. 2009. http:\/\/www.mdanderson.org\/education-and-research\/departments-programs-and-labs\/departments-and-divisions\/symptom-research\/symptom-assessment-tools\/BPI_UserGuide.pdf . Accessed. 2 Sept, 2014."},{"key":"449_CR42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/bjc.1994.137","volume":"69","author":"CJ Twelves","year":"1994","unstructured":"Twelves CJ, Dobbs NA, Lawrence MA, Ramirez AJ, Summerhayes M, Richards MA, et al. Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer. 1994;69:726\u201331.","journal-title":"Br J Cancer"},{"key":"449_CR43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2407-13-164","volume":"13","author":"L Mastro Del","year":"2013","unstructured":"Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, et al. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer. 2013;13:164.","journal-title":"BMC Cancer"},{"key":"449_CR44","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/bjc.1998.711","volume":"78","author":"AJ Ramirez","year":"1998","unstructured":"Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens RD. Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer. 1998;78:1488\u201394.","journal-title":"Br J Cancer"},{"key":"449_CR45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1524-4741.2008.00567.x","volume":"14","author":"P Hopwood","year":"2008","unstructured":"Hopwood P, Watkins J, Ellis P, Smith I. Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer. Breast J. 2008;14:228\u201335.","journal-title":"Breast J"},{"key":"449_CR46","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11136-011-9999-z","volume":"21","author":"CM Moinpour","year":"2012","unstructured":"Moinpour CM, Donaldson GW, Liepa AM, Melemed AS, O\u2019Shaughnessy J, Albain KS. Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer. Qual Life Res. 2012;21:765\u201375.","journal-title":"Qual Life Res"},{"key":"449_CR47","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129\u201338.","journal-title":"Ann Acad Med Singapore"},{"key":"449_CR48","volume-title":"Measuring the Quality of Life of Cancer Patients With the Rotterdam Symptom Checklist (RSCL): A Manual","author":"JC Haes de","year":"2012","unstructured":"de Haes JC, Olschewski M, Fayres P, Visser MRM, Cull A, Hopwood P, et al. Measuring the Quality of Life of Cancer Patients With the Rotterdam Symptom Checklist (RSCL): A Manual. Groningen, The Netherlands: Northern Centre for Healthcare Research (NCH); 2012."},{"key":"449_CR49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/pon.2960010106","volume":"1","author":"M Watson","year":"1992","unstructured":"Watson M, Law M, Maguire GP, Robertson B, Greer S, Bliss JM, et al. Further development of a quality of life measure for cancer patients: The Rotterdam Symptom Checklist (revised). Psycho-Oncology. 1992;1:35\u201344.","journal-title":"Psycho-Oncology"},{"key":"449_CR50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1023\/A:1008282806910","volume":"9","author":"JC Haes de","year":"1998","unstructured":"de Haes JC, Olschewski M. Quality of life assessment in a cross-cultural context: use of the Rotterdam Symptom Checklist in a multinational randomised trial comparing CMF and Zoladex (Goserlin) treatment in early breast cancer. Ann Oncol. 1998;9:745\u201350.","journal-title":"Ann Oncol"},{"key":"449_CR51","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.1998.16.9.3082","volume":"16","author":"AJ Bailey","year":"1998","unstructured":"Bailey AJ, Parmar MK, Stephens RJ. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee. J Clin Oncol. 1998;16:3082\u201393.","journal-title":"J Clin Oncol"},{"key":"449_CR52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0959-8049(03)00372-1","volume":"39","author":"V Chiarion-Sileni","year":"2003","unstructured":"Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer. 2003;39:1577\u201385.","journal-title":"Eur J Cancer"},{"key":"449_CR53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0959-8049(99)00341-X","volume":"36","author":"GG Duncan","year":"2000","unstructured":"Duncan GG, Philips N, Pickles T. Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer. Eur J Cancer. 2000;36:759\u201365.","journal-title":"Eur J Cancer"},{"key":"449_CR54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0959-8049(97)00347-X","volume":"34","author":"P Hopwood","year":"1998","unstructured":"Hopwood P, Harvey A, Davies J, Stephens RJ, Girling DJ, Gibson D, et al. Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. Eur J Cancer. 1998;34:49\u201357.","journal-title":"Eur J Cancer"},{"key":"449_CR55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.lungcan.2008.01.013","volume":"61","author":"K Ribi","year":"2008","unstructured":"Ribi K, Bernhard J, Schuller JC, Weder W, Bodis S, Jorger M, et al. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer. 2008;61:398\u2013404.","journal-title":"Lung Cancer"},{"key":"449_CR56","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-3959(96)03131-4","volume":"67","author":"CS Cleeland","year":"1996","unstructured":"Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain. 1996;67:267\u201373.","journal-title":"Pain"},{"key":"449_CR57","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.1999.17.9.2932","volume":"17","author":"G Kemmler","year":"1999","unstructured":"Kemmler G, Holzner B, Kopp M, Dunser M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932\u201340.","journal-title":"J Clin Oncol"},{"key":"449_CR58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102.","journal-title":"Health Qual Life Outcomes"},{"key":"449_CR59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jnci\/djq508","volume":"103","author":"J Lemieux","year":"2011","unstructured":"Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001\u20132009). J Natl Cancer Inst. 2011;103:178\u2013231.","journal-title":"J Natl Cancer Inst"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-016-0449-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:20:15Z","timestamp":1526638815000},"score":1,"resource":{"primary":{"URL":"http:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-016-0449-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1186\/s12955-016-0449-z","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,25]]},"article-number":"52"}}